October 27, 2008Catheterization and Cardiovascular Interventions
Outcome of patients treated by a novel thin‐strut cobalt‐chromium stent in the drug‐eluting stent era: Results of the SKICE (Skylor in real world practice) registry
Key result
Implantation of the Skylor thin-strut cobalt-chromium bare-metal stent in 150 patients undergoing PCI was associated with an 8.0% rate of major adverse cardiovascular events at 9 months.
Population
n=150 patients undergoing percutaneous coronary interventions selected for bare-metal stent implantation due…
Design
Cohort
Follow-up
9-month
Authors
Discussion
Loading...
Member takes
Implication
May support thin-strut BMS in selected PCI patients; leaves open randomized comparison to DES.
Study Design
Type
Observational (n=150)
Multicenter
No
Structured PICO
P
Population
150 patients undergoing percutaneous coronary interventions treated with the Skylor bare-metal stent, followed for up to 9 months.
E
Exposure
Implantation of a novel thin-strut cobalt-chromium bare-metal stent (Skylor)
O
Outcome
Major adverse cardiovascular events (MACE) up to 9-monthcomposite
In the drug-eluting stent era, the use of a novel thin-strut cobalt-chromium bare-metal stent in selected patients is associated with an 8.0% rate of MACE at 9 months.
Cite This Study
Burzotta et al. (2008) conducted an observational in Percutaneous coronary interventions (PCI) (n=150). Skylor thin-strut cobalt-chromium bare-metal-stent was evaluated on Major adverse cardiovascular events (MACE). Implantation of the Skylor thin-strut cobalt-chromium bare-metal stent in 150 patients undergoing PCI was associated with an 8.0% rate of major adverse cardiovascular events at 9 months.